title: Effects of delayed puerarin treatment in long-term neurological outcomes of focal ischemic stroke in rats.
abstract: OBJECTIVE
  The present study aimed at investigate the therapeutic effects of delayed puerarin treatment in neurological outcomes after middle cerebral artery occlusion (MCAO) in rats.
  
  
  METHODS
  Male Wistar rats were subjected to MCAO for 120 min followed by reperfusion for 14 days. Puerarin (0, 50, 100, 200 mg/kg, intra-peritoneally) was administered at 24 h after stroke onset and repeated daily for 14 days. Neurological deficits were evaluated at 1, 4, 7, 14 days after stroke. Brain infarct volume and peri-infarct context vessel density were examined at 14 days after stroke.
  
  
  RESULTS
  Puerarin significantly improved neurological functions up to 14 days after stroke and decreased the infarct volume with doses of 50 mg/kg and 100 mg/kg compared with saline controls. Puerarin treatment also significantly increased peri-infarct context vessel density at 14 days after stroke.
  
  
  CONCLUSIONS
  Delayed treatment of puerarin initiated at 24 h after stroke is beneficial with improved long-term neurological outcomes and reduced infarction volume in focal ischemic stroke in rats. Enhanced vascular remodeling by puerarin might at least partially contribute to its beneficial effects.
authors.affiliation: Department of Brain Center, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu Province 210029, China ; Department of Internal Neurology, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu Province 210029, China.
authors.forename: Minghua
authors.initials: M
authors.lastname: Wu
authors.affiliation: Department of Neurology, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province 210046, China.
authors.forename: Sen
authors.initials: S
authors.lastname: Liang
authors.affiliation: Department of Neurology, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province 210046, China.
authors.forename: Li
authors.initials: L
authors.lastname: Ma
authors.affiliation: Department of Neurology, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province 210046, China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Han
authors.affiliation: Department of Brain Center, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu Province 210029, China ; Department of Internal Neurology, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, Jiangsu Province 210029, China.
authors.forename: Xiusheng
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Neurology, The First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, Jiangsu Province 210046, China.
authors.forename: Chengcheng
authors.initials: C
authors.lastname: Xu
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D002546:Ischemic Attack, Transient / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D007529:Isoflavones / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D008516:Medicine, Chinese Traditional; D017208:Rats, Wistar; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology / Q000503:physiopathology; D061665:Time-to-Treatment; D016896:Treatment Outcome; D066253:Vascular Remodeling / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage* / Q000627:therapeutic use
chemical_list: D007529:Isoflavones; D014665:Vasodilator Agents; C033607:puerarin
keywords: Cerebrovascular remodeling; focal cerebral ischemia; long-term neurological outcomes; puerarin; rats
references.citation: Stroke. 2009 Jun;40(6):2244-50
references.pmid: 19246690
references.citation: Int J Mol Sci. 2012;13(9):11753-72
references.pmid: 23109881
references.citation: Transl Stroke Res. 2013 Jun;4(3):279-85
references.pmid: 23658596
references.citation: J Biomed Sci. 2009 Jan 19;16:9
references.pmid: 19272172
references.citation: J Ethnopharmacol. 2007 Sep 25;113(3):421-6
references.pmid: 17698307
references.citation: Stroke. 2008 Apr;39(4):1364-70
references.pmid: 18309142
references.citation: Biol Pharm Bull. 2006 May;29(5):945-50
references.pmid: 16651724
references.citation: Zhongguo Zhong Yao Za Zhi. 1995 Sep;20(9):560-2, inside backcover
references.pmid: 8679097
references.citation: Stroke. 2009 Jul;40(7):2532-8
references.pmid: 19443804
references.citation: Neuropharmacology. 2000 Mar 3;39(5):711-6
references.pmid: 10699437
references.citation: Transl Stroke Res. 2011 Jun 1;2(2):179-85
references.pmid: 21904593
references.citation: Neurol Res. 2009 May;31(4):402-6
references.pmid: 19508827
references.citation: Zhongguo Zhong Yao Za Zhi. 1997 Dec;22(12):752-4, 765
references.pmid: 11243176
references.citation: Cell Transplant. 2011;20(7):1049-64
references.pmid: 21092409
references.citation: Transl Stroke Res. 2013 Jun;4(3):308-21
references.pmid: 23682299
references.citation: Asian Pac J Trop Med. 2012 Nov;5(11):891-6
references.pmid: 23146804
references.citation: Lancet Neurol. 2012 Apr;11(4):369-80
references.pmid: 22441198
references.citation: Front Biosci (Elite Ed). 2012 Jan 01;4:809-17
references.pmid: 22201915
references.citation: Nat Med. 2006 Apr;12(4):441-5
references.pmid: 16565723
references.citation: CNS Neurol Disord Drug Targets. 2013 Mar;12(2):200-8
references.pmid: 23394537
references.citation: Eur J Pharmacol. 2006 Dec 15;552(1-3):105-11
references.pmid: 17027964
references.citation: Acta Pharmacol Sin. 2004 Aug;25(8):1045-51
references.pmid: 15301738
references.citation: Eur J Pharmacol. 2007 Nov 28;574(2-3):179-84
references.pmid: 17692311
references.citation: J Clin Pharmacol. 2013 Aug;53(8):787-811
references.pmid: 23677886
references.citation: Brain Res. 1995 Mar 13;674(1):55-62
references.pmid: 7773695
references.citation: Planta Med. 2005 Jul;71(7):585-91
references.pmid: 16041641